Inhibikase Therapeutics, which is recruiting up to 120 untreated Parkinson’s disease patients across the U.S. to test its oral therapy IkT-148009, announced that its 201 trial program just dosed its first participant. The Phase 2 trial (NCT05424276) is assessing the safety and tolerability of IkT-148009 versus a…
Acorda Therapeutics has entered into an agreement with Chance Pharmaceuticals for Inbrija (levodopa inhalation powder), a medication used to treat symptoms during off episodes in Parkinson’s disease, to become available in China. Parkinson’s is a growing problem in China due to the country’s aging population; by…
A once-daily 200 mg dose of IkT-148009, Inhibikase Therapeutics‘ investigational therapy for Parkinson’s disease, reached steady levels in the body after four days without causing any serious side effects in healthy volunteers. The company plans to include this dose in its ongoing Phase 2 study (NCT05424276) in…
The U.S. Food and Drug Administration (FDA) has requested more information about the specialized pump used to administer ABBV-951 (foslevodopa/foscarbidopa), an under-the-skin formulation of levodopa/carbidopa, before it will consider approving the therapy for motor fluctuations in people with advanced Parkinson’s disease. The agency’s complete response letter comes 10…
IMAC Holdings and Brain Scientific have agreed to merge to offer solutions that cover the spectrum of care for neurological diseases, starting from diagnosis all the way through to treatment. The collaboration will focus mainly on disease management for people with Parkinson’s disease, Alzheimer’s disease, and…
People with idiopathic Parkinson’s disease have significantly higher blood levels of neurofilament light chain (NfL) — a biomarker of nerve cell damage — than those whose Parkinson’s is associated with mutations in the LRRK2 gene, a study showed. This difference, however, held true only for the early stages of disease,…
Microglia, the brain’s resident immune cells, may contribute to Parkinson’s disease by releasing tiny vesicles filled with alpha-synuclein — the protein that builds up to toxic levels in Parkinson’s — a mouse study suggests. This release, which was associated with greater nerve cell damage and worse motor function, was…
Among several atypical antipsychotics, Nuplazid (pimavanserin) seems to be the most effective at easing Parkinson’s disease psychosis (PDP) while sparing motor function, according to a review study. Clozapine, used off-label in people with Parkinson’s, also helped, but its effect was not as large and patients were more…
People with REM sleep behavior disorder (RBD), a sleep disturbance that can precede Parkinson’s disease, have higher levels of toxic alpha-synuclein protein clumps in their stool than do Parkinson’s patients and healthy people, a study showed. Alpha-synuclein aggregates, toxic to cells, are thought to contribute to Parkinson’s and other…
Microglia — the brain’s primary immune cells — can help to keep motor symptoms of Parkinson’s disease from quickly advancing in early disease stages, work in a mouse disease model suggests. Its findings support studies indicating both a neuroprotective and damaging role for these immune cells over the disease’s…
Get regular updates to your inbox.